Evidence map›Paper›PMID 32379804›Full record

ArticlePloS one2020

Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II immunogen: Strain-specific and strain-transcending immune responses over a nine-year period.

Camila M P Medeiros, Eduardo U M Moreira, Camilla V Pires, Letícia M Torres, Luiz F F Guimarães, Jéssica R S Alves, Bárbara A S Lima, Cor J F Fontes, Helena L Costa, Cristiana F A Brito and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. IgM antibody responses againstFrontiers in cellular and infection microbiology · 2023
    Article
  4. Characterization of a novelFrontiers in immunology · 2023
    Article
  5. Article
  6. Article
  7. Frontiers in immunology · 2022
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Camila M P MedeirosCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Eduardo U M MoreiraCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Camilla V PiresCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Letícia M TorresCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Luiz F F GuimarãesCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Jéssica R S AlvesCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Bárbara A S LimaCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Cor J F FontesHospital Júlio Muller, Universidade Federal de Mato Grosso, Cuiabá, Mato Grosso, Brazil.
Helena L CostaCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Cristiana F A BritoCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Tais N SousaCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Francis B NtumngiaCenter for Global Health and Infectious Diseases Research, College of Public Health, University of South Florida, Tampa, Florida, United States of America.ORCID 0000-0001-9867-3534
John H AdamsCenter for Global Health and Infectious Diseases Research, College of Public Health, University of South Florida, Tampa, Florida, United States of America.
Flora S KanoCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.
Luzia H CarvalhoCentro de Pesquisas René Rachou/FIOCRUZ Minas, Belo Horizonte, MG, Brazil.ORCID 0000-0001-5822-4187
Fundação Oswaldo Cruz · BRUniversidade Federal de Minas Gerais · BRUniversity of South Florida · USUniversidade Federal de Mato Grosso · BR

Funding

Immunological characterization of the P. vivax DBPR01AI064478 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI ADAMS, JOHN H · 2006 to 2023
$9.6M
NIAID NIH HHS R01 AI064478
6 · The paper itself

Abstract

backgroundA low proportion of P. vivax-exposed individuals acquire protective strain-transcending neutralizing IgG antibodies that are able to block the interaction between the Duffy binding protein II (DBPII) and its erythrocyte-specific invasion receptor. In a recent study, a novel surface-engineered DBPII-based vaccine termed DEKnull-2, whose antibody response target conserved DBPII epitopes, was able to induce broadly binding-inhibitory IgG antibodies (BIAbs) that inhibit P. vivax reticulocyte invasion. Toward the development of DEKnull-2 as an effective P. vivax blood-stage vaccine, we investigate the relationship between naturally acquired DBPII-specific IgM response and the profile of IgG antibodies/BIAbs activity over time. METHODOLOGY/PRINCIPAL

findingsA nine-year follow-up study was carried-out among long-term P. vivax-exposed Amazonian individuals and included six cross-sectional surveys at periods of high and low malaria transmission. DBPII immune responses associated with either strain-specific (Sal1, natural DBPII variant circulating in the study area) or conserved epitopes (DEKnull-2) were monitored by conventional serology (ELISA-detected IgM and IgG antibodies), with IgG BIAbs activity evaluated by functional assays (in vitro inhibition of DBPII-erythrocyte binding). The results showed a tendency of IgM antibodies toward Sal1-specific response; the profile of Sal1 over DEKnull-2 was not associated with acute malaria and sustained throughout the observation period. The low malaria incidence in two consecutive years allowed us to demonstrate that variant-specific IgG (but not IgM) antibodies waned over time, which resulted in IgG skewed to the DEKnull-2 response. A persistent DBPII-specific IgM response was not associated with the presence (or absence) of broadly neutralizing IgG antibody response. CONCLUSIONS/SIGNIFICANCE: The current study demonstrates that long-term exposure to low and unstable levels of P. vivax transmission led to a sustained DBPII-specific IgM response against variant-specific epitopes, while sustained IgG responses are skewed to conserved epitopes. Further studies should investigate on the role of a stable and persistent IgM antibody response in the immune response mediated by DBPII.

Indexed as

AdultAntibodies, NeutralizingAntibody FormationAntigens, ProtozoanFemaleHumansImmunoglobulin GImmunoglobulin MMalaria VaccinesMalaria, VivaxMaleMiddle AgedPlasmodium vivaxProtozoan ProteinsReceptors, Cell SurfaceAntibodies, NeutralizingAntigens, ProtozoanDuffy antigen binding protein, PlasmodiumImmunoglobulin GImmunoglobulin MMalaria VaccinesProtozoan ProteinsReceptors, Cell Surface

Identifiers

PMID32379804
PMCPMC7205269
OpenAlexW3023714422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.